Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD) priced an underwritten registered direct offering of 18,000,000 common shares at $1.00 per share, anchored by a $15 million institutional investment, with gross proceeds of approximately $18 million. The company intends to use net proceeds for working capital and general corporate purposes.
The offering is expected to close on or about April 24, 2026, subject to customary conditions. Canaccord Genuity and BTIG are joint bookrunners. The offering is made under a Form S-3 shelf registration declared effective March 26, 2026.
Positive
- $15M anchor investment from a fundamental institutional investor
- Approximately $18M gross proceeds to support working capital
- Offering covered by effective Form S-3 (declared effective March 26, 2026)
Negative
- 18,000,000 new shares issued at $1.00, representing a material share issuance
- Potential dilution to existing shareholders due to the number of shares offered
News Market Reaction – PAVM
In the Apr 23 session, PAVM declined 2.13%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 11 | Offering closing | Negative | +1.1% | Completed public offering at $1.00 per share with $26.9M net proceeds. |
| Sep 10 | Offering pricing | Negative | -1.5% | Priced 25M-share offering at $1.00 with additional 3.75M-share option. |
| Sep 09 | Offering announcement | Negative | -1.5% | Proposed underwritten public offering under existing S-3 shelf registration. |
| Apr 11 | Offering closing | Negative | -0.3% | Closed $16.1M net offering of 14.375M shares at $1.20 per share. |
| Apr 09 | Offering pricing | Negative | -1.9% | Priced 12.5M-share offering at $1.20 with 1.875M-share option. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Past Lucid equity offerings have usually seen small negative next-day moves, with one positive outlier on a closing announcement.
Recent history for Lucid-focused capital raises shows repeated use of public offerings at low share prices. In April 2025 and September 2025, Lucid priced and then closed underwritten offerings around $1.00–$1.20 per share, raising up to about $26.9M in net proceeds. Most of these events produced modest single-day declines near the announcements, though one closing headline saw a slight positive reaction, underscoring mixed but generally cautious responses to dilution.
Key Terms
underwritten registered direct offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
joint bookrunners financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately
The offering is expected to close on or about April 24, 2026, subject to customary closing conditions.
Canaccord Genuity LLC and BTIG, LLC are acting as joint bookrunners for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-291981) declared effective by the Securities and Exchange Commission on March 26, 2026. The offering is being made only by means of a prospectus and a prospectus supplement which forms a part of the effective registration statement relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC's website at http://www.sec.gov and may also be obtained, when available, by contacting Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares of common stock. Lucid will not, and has been advised by the underwriters that they and their affiliates will not, sell any of the shares of common stock in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-18-million-underwritten-offering-of-common-stock-302751719.html
SOURCE Lucid Diagnostics